Showing results (31-40 of 53) with videos related to
Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|November 5, 2017
Facility Volume and Survival in Nasopharyngeal CarcinomaEmi J Yoshida, Michael Luu, John M David, et al.European Journal of Cancer (Oxford, England : 1990)|October 1, 2018
Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implicationsDiana J Lu, Michael Luu, Alain Mita, et al.Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery|October 30, 2019
Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapyMark P Sittig, Michael Luu, Emi J Yoshida, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2017
Metastatic Lymph Node Burden and Survival in Oral Cavity CancerAllen S Ho, Sungjin Kim, Mourad Tighiouart, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivinAnthony W Tolcher, Alain Mita, Lionel D Lewis, et al.Clinical Breast Cancer|January 8, 2014
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancerMonica M Mita, Anil A Joy, Alain Mita, et al.Cancer|December 22, 2016
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancerZachary S Zumsteg, Sungjin Kim, John M David, et al.Cancer|May 10, 2018
Quantitative survival impact of composite treatment delays in head and neck cancerAllen S Ho, Sungjin Kim, Mourad Tighiouart, et al.Plos One|September 19, 2019
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptomsEdward Wolin, Alain Mita, Amit Mahipal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.Pageof 6